You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydromorphine
Accession NumberDB01565
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionA semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIC3S5FRP6JW
CAS number509-60-4
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyIJVCSMSMFSCRME-KBQPJGBKSA-N
InChI
InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-10,14-diol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O
Pharmacology
IndicationDihydromorphine is an opioid analgesic used for moderate to severe pain relief.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinunknown
agonist
HumanP41143 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
E3 ubiquitin-protein ligase TRIM13Proteinunknown
agonist
HumanO60858 details
Pro-opiomelanocortinProteinunknown
agonist
HumanP01189 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Dihydromorphine Action PathwayDrug actionSMP00689
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydromorphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dihydromorphine.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dihydromorphine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydromorphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydromorphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydromorphine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydromorphine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Asenapine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydromorphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azaperone.Vet Approved
AzelastineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydromorphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydromorphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydromorphine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Dihydromorphine.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydromorphine.Approved, Investigational
BuprenorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydromorphine.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Dihydromorphine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydromorphine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydromorphine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dihydromorphine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydromorphine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydromorphine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydromorphine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydromorphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydromorphine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydromorphine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydromorphine.Approved, Vet Approved
CitalopramDihydromorphine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydromorphine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydromorphine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydromorphine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.Approved
DapoxetineDihydromorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.Approved
DesvenlafaxineDihydromorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydromorphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydromorphine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydromorphine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydromorphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Dihydromorphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydromorphine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dihydromorphine.Experimental, Illicit
DuloxetineDihydromorphine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dihydromorphine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efonidipine.Approved
EluxadolineDihydromorphine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydromorphine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eplerenone.Approved
EscitalopramDihydromorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydromorphine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydromorphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.Approved
EthanolDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydromorphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydromorphine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.Approved
EtoperidoneDihydromorphine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydromorphine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydromorphine.Approved, Illicit
FluoxetineDihydromorphine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydromorphine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydromorphine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydromorphine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydromorphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydromorphine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydromorphine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydromorphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydromorphine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydromorphine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dihydromorphine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydromorphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydromorphine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydromorphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydromorphine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.Approved
IndalpineDihydromorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydromorphine.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone.Approved
KW-3902The risk or severity of adverse effects can be increased when Dihydromorphine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydromorphine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydromorphine.Approved
LevomilnacipranDihydromorphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydromorphine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydromorphine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydromorphine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydromorphine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydromorphine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Dihydromorphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Dihydromorphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydromorphine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydromorphine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydromorphine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydromorphine.Approved
MethotrimeprazineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydromorphine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Dihydromorphine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydromorphine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydromorphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.Approved
MetyrosineDihydromorphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.Approved, Illicit
MilnacipranDihydromorphine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Investigational
MirtazapineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dihydromorphine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydromorphine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Investigational
NalbuphineNalbuphine may decrease the analgesic activities of Dihydromorphine.Approved
NaltrexoneThe therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDihydromorphine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydromorphine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydromorphine.Approved
OpiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Opium.Approved, Illicit
OrphenadrineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydromorphine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydromorphine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydromorphine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydromorphine.Approved
ParaldehydeDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineDihydromorphine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.Approved
PentazocinePentazocine may decrease the analgesic activities of Dihydromorphine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydromorphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydromorphine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydromorphine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydromorphine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydromorphine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDihydromorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydromorphine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydromorphine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydromorphine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydromorphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydromorphine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydromorphine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydromorphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydromorphine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dihydromorphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydromorphine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dihydromorphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dihydromorphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydromorphine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ramelteon.Approved, Investigational
RamosetronDihydromorphine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydromorphine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dihydromorphine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Romifidine.Vet Approved
RopiniroleDihydromorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine.Approved
RotigotineDihydromorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydromorphine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydromorphine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sertindole.Approved, Withdrawn
SertralineDihydromorphine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydromorphine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydromorphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.Approved
SuvorexantDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydromorphine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrodotoxin.Investigational
ThalidomideDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydromorphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydromorphine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dihydromorphine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiapride.Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydromorphine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydromorphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydromorphine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydromorphine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydromorphine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydromorphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydromorphine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydromorphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydromorphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydromorphine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydromorphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydromorphine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.Approved
VenlafaxineDihydromorphine may increase the serotonergic activities of Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydromorphine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ziconotide.Approved
ZimelidineDihydromorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zolazepam.Vet Approved
ZolpidemDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydromorphine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Herbert Merz, Ingrid Wiedemann, Helmut Ensinger, Klaus Stockhaus, Matthias Grauert, “14-hydroxy-N-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions.” U.S. Patent US5240933, issued August 31, 1993.

US5240933
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.985
Caco-2 permeable+0.8356
P-glycoprotein substrateSubstrate0.8896
P-glycoprotein inhibitor INon-inhibitor0.8653
P-glycoprotein inhibitor IINon-inhibitor0.9868
Renal organic cation transporterInhibitor0.5516
CYP450 2C9 substrateNon-substrate0.8115
CYP450 2D6 substrateSubstrate0.8647
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.797
CYP450 2C9 inhibitorNon-inhibitor0.9309
CYP450 2D6 inhibitorNon-inhibitor0.617
CYP450 2C19 inhibitorNon-inhibitor0.7678
CYP450 3A4 inhibitorNon-inhibitor0.8793
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9646
Ames testNon AMES toxic0.7901
CarcinogenicityNon-carcinogens0.9598
BiodegradationNot ready biodegradable0.9846
Rat acute toxicity2.8928 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8927
hERG inhibition (predictor II)Non-inhibitor0.8414
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.82 mg/mLALOGPS
logP1.26ALOGPS
logP1.08ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)10.29ChemAxon
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.16 m3·mol-1ChemAxon
Polarizability30.66 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and...
Gene Name:
TRIM13
Uniprot ID:
O60858
Molecular Weight:
46987.08 Da
References
  1. Liebmann C, Schnittler M, Hartrodt B, Born I, Neubert K: Structure-activity studies of novel casomorphin analogues: binding profiles towards mu 1-, mu 2- and delta -opioid receptors. Pharmazie. 1991 May;46(5):345-8. [PubMed:1654566 ]
  2. Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208. [PubMed:2828423 ]
  3. Ishizuka Y, Oka T: Relation of diltiazem binding sites to opioid receptor subtypes in the guinea-pig brain. Tokai J Exp Clin Med. 1987 Mar;12(1):11-7. [PubMed:2835832 ]
  4. Koman A, Kolb VM, Terenius L: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. Pharm Res. 1987 Apr;4(2):147-9. [PubMed:2855368 ]
  5. Ho CL, Hammonds RG Jr, Li CH: Opiate receptor binding profile in the rabbit cerebellum and brain membranes. Biochem Pharmacol. 1985 Apr 1;34(7):925-31. [PubMed:2985086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Type 4 melanocortin receptor binding
Specific Function:
ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met-enkephalin are endogenous opiates.
Gene Name:
POMC
Uniprot ID:
P01189
Molecular Weight:
29423.72 Da
References
  1. Somoza E: Influence of neuroleptics on the binding of met-enkephalin, morphine and dihydromorphine to synaptosome-enriched fractions of rat brain. Neuropharmacology. 1978 Aug;17(8):577-81. [PubMed:29252 ]
  2. Johnson N, Houghten R, Pasternak GW: Binding of 3H-beta-endorphin in rat brain. Life Sci. 1982 Sep 20-27;31(12-13):1381-4. [PubMed:6292632 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23